Performant Healthcare, Inc. Announces Preliminary Financial Results for Second Quarter 2025
Performant will no longer hold its second quarter results conference call originally scheduled for Tuesday, August 5, 2025
Share
Second Quarter 2025 Results The Company currently expects to file its Form 10-Q for the quarter ended June 30, 2025 on August 7, 2025 and anticipates reporting second quarter revenues of approximately $37.8 million, net income of approximately $2.1 million, and adjusted EBITDA of approximately $6.2 million.
Transaction with Machinify
In a separate press release issued today, Performant announced its entry into a definitive agreement to be acquired by Machinify, a healthcare intelligence leader and portfolio company of New Mountain Capital. As a result, Performant will no longer hold its second quarter results conference call originally scheduled for Tuesday, August 5, 2025. Performant is also withdrawing its previously issued full-year 2025 guidance.
Note Regarding Use of Non-GAAP Financial Measures
In this press release, the Company presents adjusted EBITDA. This measure is not in accordance with accounting principles generally accepted in the United States of America ('US GAAP') and accordingly reconciliation of adjusted EBITDA determined in accordance with US GAAP is included in the 'Reconciliation of Non-GAAP Results' table at the end of this press release. We have included adjusted EBITDA in this press release because it is a key measure used by our management and board of directors to understand and evaluate our core operating performance and trends and to prepare and approve our annual budget. Accordingly, we believe that adjusted EBITDA provides useful information to investors and analysts in understanding and evaluating our operating results in the same manner as our management and board of directors. Our use of adjusted EBITDA has limitations as an analytical tool and should not be considered in isolation or as a substitute for analysis of our results as reported under US GAAP. In particular, many of the adjustments to our US GAAP financial measures reflect the exclusion of items, specifically interest, tax, and depreciation and amortization expenses, equity-based compensation expense and certain other non-operating expenses that are recurring and will be reflected in our financial results for the foreseeable future. In addition, these measures may be calculated differently from similarly titled non-GAAP financial measures used by other companies, limiting their usefulness for comparison purposes.
ABOUT PERFORMANT
Performant supports healthcare payers in identifying, preventing, and recovering waste and improper payments by leveraging advanced technology, analytics and proprietary data assets. Performant works with leading national and regional healthcare payers to provide eligibility-based, also known as coordination-of-benefits (COB) services, as well as claims-based services, which includes the audit and identification of improperly paid claims. Performant is a leading provider of these services in both government and commercial healthcare markets. Performant also provides advanced reporting capabilities, support services, customer care, and stakeholder training programs designed to mitigate future instances of improper payments.
To learn more about Performant, please visit www.performanthealthcare.com
Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's outlook for revenues, net income (loss), and adjusted EBITDA in 2025 and beyond. These forward-looking statements are based on current expectations, estimates, assumptions, and projections that are subject to change and actual results may differ materially from the forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: the Company's ability to generate revenue following long implementation periods associated with new customer contracts; client relationships and the Company's ability to maintain such client relationships; our commercial client growth strategy; many of the Company's customer contracts being subject to periodic renewal, not being exclusive, and not providing for committed business volumes; anticipated trends and challenges in the Company's business and competition in the markets in which it operates; the Company's indebtedness and compliance, or failure to comply, with restrictive covenants in the Company's credit agreement; opportunities and expectations for growth in the various markets in which the Company operates; the Company's ability to hire and retain employees with specialized skills that are required for its healthcare business; downturns in domestic or global economic conditions and other macroeconomic factors; the Company's ability to generate sufficient cash flows to fund our ongoing operations and other liquidity needs; the impact of public health emergencies, such as the COVID-19 pandemic, on the Company's business and operations, opportunities and expectations for the markets in which the Company operates; the impacts of a failure of the Company's operating systems or technology infrastructure or those of third-party vendors and subcontractors; the impacts of a cybersecurity breach or related incident to the Company or any of the Company's third-party vendors and subcontractors; the adaptability of the Company's technology platform to new markets and processes; the Company's ability to invest in and utilize data and analytics capabilities to expand our capabilities; the Company's growth strategy of expanding in existing markets and considering strategic alliances or acquisitions; the Company's ability to maintain, protect and enhance its intellectual property; expectations regarding future expenses; expected future financial performance; and the Company's ability to comply with and adapt to industry regulations and compliance demands.
More information on potential factors that could affect the Company's financial condition and operating results is included from time to time in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's annual report on Form 10-K for the year ended December 31, 2024 and subsequently filed reports on Forms 10-Q and 8-K. The forward-looking statements are made as of the date of this press release and the Company does not undertake to update any forward-looking statements to conform these statements to actual results or revised expectations.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Why Shopify Stock Is Rising Today
Key Points Investors may be responding to the fact that the E.U. said it won't increase tariffs on the U.S. just yet. But slowing job growth and uncertainty around tariffs could eventually weigh on the economy. Shopify investors should keep a close watch on the company's upcoming quarterly results. 10 stocks we like better than Shopify › Shares of the e-commerce platform company Shopify (NASDAQ: SHOP) were rebounding today after stumbling on Friday after a weaker-than-expected jobs report. Investors regained some of their optimism for the company today, as the European Union says it's delaying some retaliatory tariffs on the U.S. for six months. Shopify investors are closely watching for any positive economic news as they prepare for the company's Q2 earnings report due out on Wednesday. Shopify stock was up by more than 5% this morning and had gained 4.8% as of 11:29 a.m. ET. Some positive news ahead of Shopify's upcoming earnings report Profit growth has been slowing for Shopify, and investors will get more details on which direction it's currently headed when the company reports second-quarter results on Wednesday. In the meantime, investors were responding positively to the E.U.'s announcement that it will hold off on any retaliatory tariffs against the U.S., as it tries to strike a trade deal. Investors were spooked on Friday by a weak jobs report for June and significantly revised jobs numbers for May, which caused a sell-off among many stocks on Friday. So any news that the U.S. isn't entering a new stage of a trade war with the E.U. caused investors to respond positively. Shopify's growth is dependent on how well companies are growing in the U.S. and how many new businesses are started. So any slowdown in the economy will weigh down the company's sales and earnings. The latest job data wasn't a good sign, but with today's gains, it appears investors aren't yet sold on the idea that the U.S. economy is slowing down. Shopify investors will know more very soon Wednesday's Q2 report will prove whether investors' optimism is misplaced or not. It's certainly not time to panic about the economy, but there are significant uncertainties right now as hiring slows down and the dust settles on new tariffs. It could take months for both to work their way through the economy, which means the next few quarters will be especially important to watch for Shopify investors. Should you invest $1,000 in Shopify right now? Before you buy stock in Shopify, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Shopify wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Chris Neiger has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Shopify. The Motley Fool has a disclosure policy. Why Shopify Stock Is Rising Today was originally published by The Motley Fool
Yahoo
12 minutes ago
- Yahoo
A 12-Stock Sane Portfolio for Crazy Times
August 4, 2025 -- (Maple Hill Syndicate) In today's higher-tariff world, where political and geopolitical clashes are harsh, you might want to take your stock portfolio's risk level down a notch. Perhaps the Sane Portfolio can be of some help. This is a theoretical portfolio, intended to be slightly on the low-risk side of the risk spectrum. It contains a dozen stocks, and I refresh the list once a year. To get in, a stock must meet seven criteria, described below. Once I choose a stock, it stays in unless it flunks one of the seven criteria. Warning! GuruFocus has detected 4 Warning Signs with BCC. Over 23 years, the Sane Portfolio has averaged an 11.2% annual return. That slightly beats the Standard & Poor's 500 Total Return Index, with an average return of 10.8%. My column results are hypothetical and shouldn't be confused with results I obtain for clients. Past performance doesn't predict the future. My list from a year ago trailed far behind the S&P. It posted a 6.9% return while the index returned 21.9%. My worst performer was Boise Cascade Co. (NYSE:BCC), down 30%. My best was Monarch Casino & Resort Inc. (NASDAQ:MCRI), up 45%. Seven Boxes To be eligible for the Sane Portfolio, a stock must satisfy seven criteria. No single criterion is especially hard, but few companies can check all seven boxes. Market value of at least $1 billion. Debt less than stockholders' equity. Return on stockholders' equity of 10% or better. Stock price less than 18 times per-share earnings. Stock price less than 3 times per-share sales. Stock price less than 3 times book value (corporate net worth per share). Five-year earnings growth averaging 5% per year or better. This year, seven Sane Portfolio companies stay on from previous years. Winning Streaks D.R. Horton Inc. (NYSE:DHI), the nation's largest homebuilder, is back for a sixth consecutive year. Many buyers can't afford a home at today's mortgage rates. So, Horton's latest year was soggy, but it has grown revenue at a 17% clip for the past decade. Back for a fifth year is Paccar Inc. (NASDAQ:PCAR), which builds heavy trucks (Kenworth and Peterbilt). The latest year has been rough. Companies have been reluctant to spend on trucks, amid tariff uncertainty. But Paccar has achieved 11% annual earnings growth in the past decade. Boise Cascade Co. (NYSE:BCC) of Boise, Idaho, which makes engineered-wood products and plywood, hangs in there for a fourth year. As noted above, this stock was a dog in the past twelve months. However, the stock looks cheap to me at about 10 times earnings. After a gain of around 30% in the past 12 months, W.R. Berkley Corp. (NYSE:WRB) returns for a third engagement. It's a commercial casualty insurance company based in Greenwich, Connecticut. Second-Timers Three companies are in the Sane Portfolio as sophomores. One is EOG Resources Inc. (NYSE:EOG), a big Houston-based oil and gas producer that emerged from the remnants of the Enron empire. Its profitability is impressive, with a 21% return on stockholders' equity. Another sophomore is Academy Sports & Outdoors Inc. (NASDAQ:ASO), a chain of sporting goods stores headquartered in Katy, Texas. I'm concerned that it gets a lot of its merchandise from China, so it may be hard-hit by tariffs. If it can stay on this roster another year, I'll be impressed. Returning, too, is Photronics Inc. (NASDAQ:PLAB), which makes photomasks using in manufacturing semiconductor chips. Profits vary from year to year, but the company, based in Brookfield, Connecticut, has shown positive earnings ten years in a row. Newbies Five companies dropped out of the Sane Portfolio, giving me five slots to fill. I'll start with Axcelis Technologies Inc. (NASDAQ:ACLS), based in Beverly, Massachusetts. Like Photronics, it makes equipment for manufacturing semiconductor chips. Its specialty is ion implantation. Block Inc. (NYSE:XYZ) operates the Square payments system. Small businesses like its hardware and software, and it's been growing nicely. Profits have shot up at a 30% annual rate the past five years. Cactus Inc. (NYSE:WHD), which makes oil-drilling equipment, is based in (where else?) Houston, Texas. I particularly like its balance sheet, with debt only 4 percent of stockholders' equity. Cigna Group (NYSE:CI), one of the largest U.S. health insurers, has been a stodgy stock. But I think it would hold up well if the market turns rocky. Analysts expect earnings to rise. Crocs Inc. (NASDAQ:CROX) makes casual shoes with holes for ventilation or decoration. It was a fad stock several years ago, rising 104% from mid-2006 to the end of 2007. Now it seems attractively cheap to me at six times earnings. Disclosure: I own D.R. Horton for one client. John Dorfman is chairman of Dorfman Value Investments LLC in Boston, Massachusetts, and a syndicated columnist. His firm or clients may own or trade securities discussed in this column. He can be reached at jdorfman@ This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
15 minutes ago
- Associated Press
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Replimune Group (REPL) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
ATLANTA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Replimune Group, Inc. ('Replimune' or the 'Company') (NASDAQ: REPL). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information, including allegations that: (1) Defendants recklessly overstated the IGNYTE trial's prospects, given material issues that defendants knew or should have known of, which resulted in the FDA deeming the IGNYTE trial inadequate and not well-controlled; and (2) as a result, defendants' statements about Replimune's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times. If you purchased shares of Replimune between November 22, 2024 and July 21, 2025, and experienced a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at [email protected], by toll-free telephone at (888) 508-6832, or by visiting the firm's website at for more information. The deadline to ask the court to be appointed lead plaintiff in the case is September 22, 2025. Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, and 2023, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content. CONTACT: Corey Holzer, Esq. (888) 508-6832 (toll-free) [email protected]
